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Abstract: Basal insulin analogs are used to minimize unpredictable processes of NPH insulin. 
Modification of the human insulin molecule results in a slower distribution to peripheral target 
tissues, a longer duration of action with stable concentrations and thus a lower rate of hypo-
glycemia. Insulin detemir is a basal insulin analog that provides effective therapeutic options 
for patients with type 1 and type 2 diabetes. For glycemic control, no significant differences 
were found in HbA1c levels compared with NPH and insulin glargine. It is comparable with 
insulin glargine in significantly reducing rates of all types of hypoglycemia. Clinical studies 
have demonstrated that detemir is responsible for significantly lower within-subject variability 
and no or less weight gain than NPH insulin and glargine. Recent pharmacodynamic studies 
have shown that detemir can be used once daily in many patients with diabetes. Together with 
patient-friendly injection devices and dose adjustments, it provides a treatment option with the 
potential to lower the key barriers of adherence to insulin therapy in type 2 diabetes. Recent 
guidelines for treatment of type 2 diabetes suggest starting intensive therapy of hyperglycemia 
at an early stage of diabetes and recommend therapeutic options that provide the possibility of 
reaching HbA1c goals individually, with a low risk of hypoglycemia or other adverse effects of 
treatment. The properties of insulin detemir match these requirements.
Keywords: insulin analog, insulin detemir, diabetes mellitus, hypoglycemia, within-subject 
variability
Introduction
Diabetes mellitus (DM) is defined by the American Diabetes Association Expert 
  Committee as a group of metabolic diseases characterized by hyperglycemia resulting 
from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia is 
associated with long-term damage, dysfunction and failure of various organs, especially 
the eyes, kidney, nerves, heart and blood vessels.1
Type 1 diabetes mellitus (type 1 DM) is caused by absolute insulin deficiency 
resulting from autoimmune destruction of pancreatic B-cells. The autoimmune insulitis 
is characterized by a presence of auto-reactive T-lymphocytes and auto-antibodies 
against the antigen structures of B-cells. An approximate population incidence of 
type 1 DM is 25/100,000 with the highest incidence at the age of 13 to 15.2 However, 
significant ethnic differences have been found, with the lowest incidence in China and 
Japan (0.4 and 1.6/100 000, respectively)1 and the highest in Finland (40/100,000).3 
For the etiopathology of type 1 DM, the substitution of missing insulin represents the 
only therapeutic option. Since publication of the DCCT trial, most of the patients with 
type 1 DM are treated using an intensified regimen of basal-bolus therapy.4Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Type 2 diabetes mellitus (type 2 DM) is a heterogenous 
metabolic disorder characterized by a relative insulin defi-
ciency resulting from a reduced sensitivity of tissues to insulin 
and impairment of insulin secretion from pancreatic B-cells. 
Some patients are characterized by predominant insulin 
resistance and relative insulin insufficiency, while the others 
have a major defect in insulin secretion combined with insulin 
resistance. Type 2 DM represents more than 80% of the DM 
cases. The prevalence of type 2 DM is growing much more 
than has been previously estimated, in particular due to the 
increasing prevalence of obesity. It has been documented that 
earlier initiation of insulin therapy in type 2 DM, before the 
development of severe comorbidities, is required for improve-
ment of metabolic control and prevention of microvascular 
and macrovascular   complications.5 A therapeutic approach of 
earlier insulin initiation may have a role in the protection of 
B-cells from functional impairment due to long-term influence 
of hyperglycemia.6 Addition of insulin to oral anti-diabetic 
therapy (OAD) has been traditionally started with basal NPH 
(neutral protamine Hagedorn) insulin.
Until the recent introduction of basal insulin analogs, NPH 
insulin has been the most frequently used basal insulin, usually 
administrated in the evening. It is characterized by peaks in 
plasma insulin concentrations 5 to 10 hours after administra-
tion, increased risk of hypoglycemia during the night, and a 
duration of action of approximately 12 to 18 hours that may 
contribute to hyperglycemia in the morning. Common dif-
ferences in crystal size and inadequate resuspension make 
absorption kinetics and dosing precision with NPH insulin 
variable and result in unpredictable glucose levels.7
Therefore, it was important to develop new basal insulins 
to minimize these concerns. The introduction of basal insulin 
analogs has resulted in a series of clinical trials that provide 
information on the most effective way of using these insulins 
in the treatment of type 1 and 2 DM.8 The aim of this paper 
is to review new data on insulin detemir since the previous 
publication on this subject in this journal.9
Pharmacokinetics
Insulin detemir is a soluble derivative of human insulin 
(LysB29(N-tetradecanoyl) des (B30) human insulin), in which 
the threonine residue at position B30 of the human insulin 
molecule has been removed and a 14-carbon fatty acid 
side-chain has been attached to position B29. It has been 
demonstrated that insulin detemir has a faster dissociation 
from the insulin receptor and, thus, a lower molar potency 
than human insulin. This is why insulin detemir is formulated 
at a 4-fold higher molar concentration than human insulin. The 
protracted action of insulin detemir is mediated by the strong 
self-association of insulin detemir hexameric molecules at the 
injection site and albumin binding via the myristic fatty acid 
side-chain. The rate of absorption is limited by the low con-
centration of insulin detemir available for diffusion through 
the tissue and passage across the capillary wall. The fatty acid, 
myristic acid, enables insulin detemir to bind to albumin in 
the subcutaneous tissue and interstitium. More than 98% of 
insulin detemir in the bloodstream is albumin bound, which 
makes detemir more slowly distributed to peripheral target 
tissues compared to NPH insulin.10 The addition of the fatty 
acid also allows insulin detemir to be formulated as a solute 
in a neutral liquid solution, which does not precipitate during 
administration or absorption. This stable, soluble profile of 
insulin detemir contrasts with that of insulin glargine which 
precipitates from its acidic solution in the neutral subcu-
taneous tissues after injection.11 Because precipitation and 
dissolution of a precipitate are unpredictable processes, the 
mechanism of protracted absorption of insulin detemir may 
contribute to reduced variability in insulin detemir action.
These pharmacological properties have been suggested 
to be responsible for significantly lower within-subject 
variability than NPH and insulin glargine, which has been 
demonstrated in clamp studies of type 1 DM across all age 
groups.12–14
The examination of time-action profiles and the dose-
response relationship of detemir and NPH insulin in African 
Americans, Hispanic/Latinos and Caucasians with type 2 DM 
was done using a double-blind crossover trial.15 Each patient 
took part in six 16-hour isoglycemic glucose clamps (clamp 
target 7.2 mmol/L) and was randomly allocated to 3 doses 
(0.3, 0.6 and 1.2 IU/kg) of detemir and NPH, respectively. 
Comparable results were obtained for pharmacokinetics for 
all the ethnic groups. These results suggest that similar dos-
ing recommendations can be used for detemir in type 2 DM 
patients belonging to different ethnic groups.
Pharmacodynamics
Insulin detemir was originally licensed for once- or twice-
daily administration. A pharmacodynamic clamp study in 
type 1 DM comparing detemir with NPH insulin has shown 
that insulin detemir at a dose of 0.4 IU/kg had an average 
duration of action of 20 hours, which was significantly longer 
than that of NPH insulin.16
The repeat-clamp study that compared the pharmacody-
namic profile of the two basal analogs and NPH insulin in 
type 1 DM had, as its primary objective, the examination of 
within-subject variability.13 This study has shown signifi-Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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cantly lower within-subject variability of insulin detemir than 
that of the comparators. The continued duration of action at 
24 hours of studied insulins was 14% for NPH insulin, 24% 
for insulin detemir and 39% for glargine. Porcellati et al17 
compared the pharmacodynamics of basal insulin analogs 
in 24 patients with type 1 DM after a 2-week treatment with 
either glargine or detemir once daily in a randomized, double-
blind, crossover study. Glucose infusion rate was similar 
with detemir and glargine for the first 12 hours. However, 
plasma glucose increased progressively after 16 hours with 
detemir demonstrating a lower effect than insulin glargine 
during the period of 12 to 24 hours.
In another randomized, double-blind trial with 3 eugly-
cemic glucose clamp experiments, 27 insulin-treated patients 
were examined. They received 0.4, 0.8 and 1.4 IU/kg of 
either insulin detemir or glargine. The duration of action 
was comparable between the two analogs and it increased 
with a rise in the doses. Within-subject variability was lower 
for detemir, and between-subject variability did not differ 
between treatments.18 Recently, a double-blind, randomized, 
crossover study in patients with type 2 DM examined the 
glucose-lowering effect of detemir and glargine, using an 
assessment of continuous glucose monitoring. Over a 24-hour 
period, once-daily dosing with insulin detemir provided a 
similar glycemic control to that of insulin glargine after both 
had been titrated to the same glucose target.19
Despite a lower rate of hypoglycemia in patients treated 
with basal insulin analogs, it is important to study symptom 
awareness of either insulin treatment. Hormone and symp-
tom response in healthy subjects was tested during a hypo-
glycemic clamp with insulin detemir and human insulin in 
random order.20 Insulin detemir increased symptom aware-
ness during hypoglycemia (sweating, especially, was earlier 
and faster) compared to human insulin in healthy individuals, 
whereas counter-regulatory hormone response and cognitive 
function were unaltered.
Detemir in pregnancy
Until now, there are no clinical studies or reports on the use 
of insulin detemir in pregnant women with diabetes. However, 
clinical studies are ongoing. Animal reproduction studies in 
rabbits and rats revealed no significant differences between 
insulin detemir and human insulin for embryotoxicity and 
teratogenicity.21
Efficacy and safety in type 1 DM
The initial studies in type 1 DM compared effects on glucose 
metabolic parameters and the safety profile of a twice-daily 
insulin detemir administration with NPH insulin. These 
studies used a basal-bolus regimen, and were randomized 
and open-  label, since the insulin detemir is injected as a 
solution and NPH insulin as a suspension. Their duration 
was at least 20 weeks. Most of these studies have shown a 
favorable effect of insulin detemir on body weight compared 
to NPH insulin.
Singh et al22 published a meta-analysis of randomized 
controlled trials which reported data and comparisons in 
patients with type 1 and type 2 DM treated with insulin 
analogs versus regular human insulin or one long-acting 
insulin analog versus another. Results on hemoglobin HbA1c 
(HbA1c), hypoglycemia, quality of life, complications and 
adverse effects were presented. The authors did not focus 
on such outcomes as fasting plasma glucose, 2-hour post-
prandial glucose, body weight, plasma lipids or blood pres-
sure. The precise methodology of data extraction analysis was 
described. In a pooled analysis of 7 trials comparing insulin 
detemir and NPH insulin in 2558 type 1 DM adult patients, 
no significant differences in HbA1c were found, but statisti-
cally significant reductions in the risk of severe hypoglycemia 
(relative risk [RR] 0.74, 95% confidence interval [CI] 0.58 
to 0.96) and nocturnal hypoglycemia (RR 0.92, 95% CI 0.85 
to 0.98) were demonstrated.
Recent randomized studies examined the efficacy and 
safety of once- and twice-daily detemir in comparison with 
NPH or insulin glargine (Table 1). Insulin glargine and 
insulin detemir, each compared with NPH insulin, were 
examined by Pieber et al23 to study glycemic control and risk 
of hypoglycemia of twice-daily insulin detemir with once-
daily insulin glargine in 320 subjects with type 1 DM. The 
treatment did not show any significant differences in body 
weight gain between insulin detemir and insulin glargine, or 
a difference in HbA1c. But the risk of severe hypoglycemia 
(RR 0.25, 95% CI 0.07 to 0.86) and the rate ratios for severe 
and nocturnal hypoglycemia were statistically significantly 
lower in favor of insulin detemir.
A trial comparing insulin detemir versus NPH insulin in 
children and adolescents with type 1 DM,24 did not show any 
differences in HbA1c or frequency of severe hypoglycemia. 
However, benefits in favor of insulin detemir were found in 
a lower risk of nocturnal hypoglycemia. In this study, lower 
and more predictable fasting plasma glucose and lower 
body mass index were also advantages of the treatment with 
insulin detemir.
Recent studies have suggested25 that insulin detemir has 
a pharmacodynamic profile which allows its administration 
once daily. The treat-to-target ADAPT study26 examined Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
402
Raslova
effects of insulin detemir in a basal-bolus insulin regimen in 
520 patients with type 1 DM who were randomly assigned 
to receive detemir once or twice daily with insulin aspart. 
Insulin doses were titrated over 1 month. After 3 months of 
follow-up, a majority of patients continued with a twice-daily 
regimen, with an additional 3-month follow-up. The authors 
found that the most suitable routine starting schedule for 
detemir in a basal-bolus regimen for type 1 DM was once-
daily injection.
Another study had a primary objective to determine 
whether insulin detemir was non-inferior to insulin 
glargine in a basal-bolus regimen, with insulin aspart 
as the mealtime insulin, in terms of glycemic control 
in 443 patients with type 1 DM.27 At this multinational, 
open-label, parallel-group, treat-to-target, non-inferiority 
trial the patients were randomized in a 2:1 ratio to receive 
either detemir or glargine for 52 weeks. The basal insulin 
was initially administered once daily in the evening in both 
Table 1 Recent randomized trials in type 1 diabetes mellitus
Study Therapy and objectives Summary of results
Pieber et al23  
N = 320 
26-week  
Randomized, multicenter, open-label, 
parallel-group
Comparison of glycemic control and risk of  
hypoglycemia of twice-daily insulin detemir  
with once-daily insulin glargine
Det vs Glar, P  
HbA1c -0.6% vs -0.5%, ns 
FPG 7.7 vs 7.0, 0.001 
Severe and noctur -72% vs -32%, 0.05 
hypoglycemia 
within-subject variability, ns 
Overall hypoglycemia ns 
Body weight, ns
Robertson et al24 
N = 347 children 
26-week 
Randomized (2:1), multicenter,  
open-label, parallel-group
Efficacy and safety of detemir vs NPH. 
Once- or twice-daily according to the  
pre-study regimen, plus premeal insulin aspart
Det vs NPH, P 
HbA1c -0.8% vs -0.8%, ns 
FPG 8.4 9.6 0.02 
within-subject SD 3.3 vs SD 4.3, 0.001 
variability 
BMi Z-score 0.08, 0.26, 0.001 
Overall hypoglycemia, ns 
Noctur hypoglycemia was 26% less 
with detemir (P = 0.04)
Bartley et al28 
N = 497 
24-month 
Randomized(2:1), multicenter,  
open-label, parallel-group, treat-to-target
Long-term efficacy and safety of detemir vs  
NPH, plus premeal insulin aspart. Basal  
insulin initiated once daily, titrated based  
on PG levels, aiming for pre-breakfast and  
pre-dinner targets # 6.0 mmol/L
Det vs NPH, P 
HbA1c -0.94% vs -0.72%, 0.02 
FPG 8.3 9.4 0.02 
Body weight +1.7 +2.7, 0.02 
Major and noctur -69% vs -46%, 0.001 
hypoglycemia
Le Floch et al26 
N = 520 
7-month 
Randomized, multicenter,  
open-label, treat-to-target
Comparison of the efficacy and safety of  
once- and twice-daily detemir, plus  
premeal insulin aspart. After 4-month  
therapy twice-daily switched to once-daily
Det once vs Det twice, P 
HbA1c 8.1% vs 8%, ns 
Detemir doses 29 vs 39, 0.001 
No difference in the body weight and the  
ftrequency of hypoglycemia
Heller et al27 
N = 443 
52-week 
Randomized (2:1), multicenter,  
open-label, treat-to-target non-inferiority
Comparison of detemir with glargine, plus  
premeal insulin aspart. Detemir initiated  
once daily, titrated based on PG levels, if  
not achieved the pre-dinner targets  
patients switched to twice-daily detemir
Det vs Glar, P 
HbA1c -0.53% vs -0.54%, ns 
HbA1c , 7%, 32% vs 29%, ns 
without major 
hypoglycemia 
FPG 8.6 vs 8.8, ns 
No difference in hypoglycemia 
No difference in body weight 
Total basal doses 0.4 iU/kg vs 0.33 iU/kg, ns 
34.2% participants completed on once-daily 
Det with mean daily dose of 0.33 U/kg and 
65.8 of them on twice-daily with mean daily 
dose of 0.47 iU/kg. Mean daily dose of Glar 
was 0.33 iU/kg
Abbreviations: Det, detemir; Glar, glargine; Det once, detemir once-daily; Det twice, detemir twice-daily; FPG, fasting plasma glucose; noctur, nocturnal; NPH, neutral 
protamine Hagedorn; ns, not significant; PG, plasma glucose; SD, standard deviation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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groups; if patients in the detemir group were achieving 
the plasma glucose target before breakfast but not before 
dinner, they were switched to twice-daily administration. 
Glargine was administered once daily throughout the 
trial, according to its approved labeling. At the end of 
the study HbA1c levels, rates of hypoglycemia, estimated 
mean fasting plasma glucose (FPG) or insulin doses did 
not differ significantly between the detemir and glargine 
groups. Approximately one third of the patients with 
detemir completed the trial on once-daily and the rest of 
them on twice-daily administration. The basal insulin dose 
was higher in patients receiving detemir twice rather than 
once daily (0.47 vs 0.33 IU/kg, respectively).
The long-term efficacy and safety of insulin detemir 
compared to NPH insulin was examined in a 2-year, ran-
domized, controlled trial in patients with type 1 DM using 
a treat-to-target basal-bolus regimen with insulin aspart.28 
In this study, 22% of patients treated with insulin detemir 
reached a HbA1c # 7.0% in the absence of confirmed hypo-
glycemia during the last month of treatment vs 13% on NPH 
insulin (P = 0.02). Detemir was associated with a 69% lower 
risk of major hypoglycemic episodes compared to NPH 
(P , 0.001). The risk of nocturnal hypoglycemia was 46% 
lower with detemir than with NPH (P , 0.001). Moreover, 
patients treated with detemir gained less weight (detemir 
1.7 kg, NPH 2.7 kg; P = 0.02).
A large, multi-national, prospective, observational study 
PREDICTIVE29 evaluated the safety and efficacy of insulin 
detemir in patients with diabetes in daily practice. The 
European cohort included 20,531 patients. A subgroup of 
4782 type 1 DM patients was transferred from a basal-bolus 
regimen with NPH insulin (n = 3117) or insulin glargine 
(n = 1665) to insulin detemir basal-bolus therapy; or from 
a human insulin basal-bolus regimen (n = 570) to insulin 
detemir/insulin aspart. After mean follow-up of 14.4 weeks 
HbA1c and hypoglycemia were reduced by 0.6% and 54% 
(P , 0.0001, respectively) with weight neutrality. Mean 
fasting glucose and within-patient fasting glucose variability 
significantly decreased in all patients (P , 0.0001).
Efficacy and safety in type 2 DM
A clinical situation during the development of type 2 DM is 
that it might be inadequately controlled by OADs. A typical 
response is to intensify the therapeutic regimen. Intensive 
treatment of patients with type 2 DM is in line both with the 
consensus algorithm and the guidelines.30
In 2007, a Cochrane database analysis was published 
that evaluated advantages of the treatment with basal 
insulin analogs in comparison with NPH insulin in type 2 
DM. Six studies with insulin glargine and two studies with 
detemir were analyzed. Their duration was from 24 to 
54 weeks. No differences between basal insulin analogs 
and NPH insulin in HbA1c have been shown; however, a 
significantly lower rate of symptomatic, overall and noc-
turnal hypoglycemia were found in favor of basal insulin 
analogs.31 This review concluded: “For insulin therapy 
in diabetes mellitus, NPH is an effective, safe substance 
which has been tested over decades. In such cases where 
a proven effective therapy is available, the introduction of 
new substances should only be advised if there is a major 
improvement in efficacy, or if the new substance is proven 
both effective and safe”.
In the meantime, from this Cochrane analysis new data 
on the significance of hypoglycemia for the risk of fatal 
cardiovascular complications in patients with type 2 DM 
were published.32 For these novel findings, the importance 
of lowering the risk of hypoglycemia has become a major 
issue of the treatment. This was also reflected in a recent 
Consensus Statement of the American Association of Clinical 
Endocrinologists/American College of Endocrinology. The 
authors of this document recommend achieving an HbA1c of 
6.5% as the primary goal of the treatment of type 2 DM.33 
A novel statement of this panel is to use the basal synthetic 
analogs, insulin glargine and insulin detemir, instead of 
NPH insulin because the basal analogs provide a relatively 
peakless profile for approximately 24 hours and yield better 
reproducibility and consistency, both between patients and 
within patients, and a corresponding reduction in the risk of 
hypoglycemia.
First were two studies with insulin detemir in type 
2 DM with a similar design. They were multinational, 
open-label, randomized, parallel group trials comparing 
efficacy and safety of basal-bolus therapy using either insu-
lin detemir in combination with meal-time insulin aspart 
versus NPH insulin in combination with meal-time regular 
human insulin34 or basal-bolus insulin regimen comprising 
either insulin detemir or NPH insulin both in combination 
with mealtime insulin aspart.35 Patients received basal 
insulin either once or twice daily according to their pretrial 
insulin treatment and insulin aspart or regular insulin at 
mealtimes. In the first study,34 a 22-week long therapy of 
395 people with type 2 DM resulted in comparable HbA1c 
between treatments, with decreases from their baselines 
of 0.65% and 0.58% in the detemir and the NPH group, 
respectively. Treatment with insulin detemir + aspart 
was associated with a significantly lower within-person Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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variation in   self-measured FPG, as well as a lower body 
weight gain than that of NPH plus regular insulin (0.51 
versus 1.13 kg, P = 0.038). The relative risk of nocturnal 
hypoglycemia was significantly lower in the detemir group 
(RR 0.54, 95% CI 0.30 to 0.97; P , 0.04).
In a second study,35 a 26-week long therapy of 505 
patients resulted in comparable glycemic control but sig-
nificantly lower within-subject variability and less weight 
gain in the detemir group compared to patients treated with 
NPH insulin (1.0 and 1.8 kg, respectively, P = 0.017). Insulin 
detemir was well tolerated and had a similar safety profile 
to NPH insulin.
Efficacy and tolerability of insulin detemir or NPH 
insulin added to oral therapy for type 2 DM was examined 
in a treat-to-target titration protocol.36 In a parallel-group, 
multicenter trial, 476 patients with high levels of HbA1c 
were randomized to addition of twice-daily insulin detemir 
or NPH insulin. Over 24 weeks, insulin doses were titrated 
toward pre-breakfast and pre-dinner plasma glucose targets 
of #6.0 mmol/L. This resulted in comparable reductions of 
HbA1c for detemir and NPH (from 8.6 to 6.8 and from 8.5 to 
6.6%, respectively). Compared with NPH insulin, in patients 
treated with insulin detemir the risk for all and for nocturnal 
hypoglycemia was reduced by 47% and 55%, respectively 
(P , 0.001). They profited as well from significantly lower 
weight gain.
Another trial examined the effect of an evening detemir, 
a pre-breakfast detemir, or an evening NPH insulin admin-
istered at initial doses of 10 IU in 498 patients treated 
with $1 OAD.37 Similar reductions of HbA1c of all three 
regimens were found after titration of administered insulins. 
All-day and nocturnal hypoglycemia were reduced signifi-
cantly with morning and evening detemir. Nocturnal hypo-
glycemia was reduced further, by 87%, with morning detemir 
compared with evening NPH (P , 0.001). Less weight gain 
was observed for evening detemir vs NPH (P = 0.005).
In a 26-week multinational, multicenter, randomized treat-
to-target trial, OADs were discontinued and subjects were 
randomized to analog basal-bolus therapy (insulin detemir 
once daily and insulin aspart at mealtimes) or biphasic insulin 
aspart 30, twice daily.38 Both insulin analog regimens enabled 
a majority of people with type 2 DM to reach HbA1c # 7.0% 
after the failure of OADs and OAD-basal insulin therapy. 
Insulin-treated patients had more benefit from the transfer to 
analog basal-bolus therapy, while insulin-naive individuals 
had more benefit from the biphasic analog regimen.
Insulin detemir was compared with insulin glargine in the 
following randomized controlled trials (Table 2):
1.  The study by Hollander et al39 was one of the first to 
directly compare the efficacy of detemir with glargine in 
a basal-bolus regimen in patients with type 2 diabetes. It 
was a multinational, 52-week, open label,   parallel-group, 
non-inferiority, treat-to-target trial. Type 2 DM patients 
who had been receiving an OAD or insulin (with or 
without OADs) were randomized in a 2:1 ratio to receive 
insulin detemir or glargine. Detemir could be adminis-
tered once or twice daily, glargine was administered once 
daily. Insulin aspart was given at mealtimes. Insulin secre-
tagogs and α-glucosidase inhibitors were discontinued 
at study entry, but other existing OADs were continued. 
Doses of detemir and glargine were titrated to achieve a 
pre-breakfast (and pre-dinner for detemir administered 
twice daily) plasma glucose target of #6.0 mmol/L. At 52 
weeks, decreases of HbA1c from baseline for detemir and 
glargine were similar at -1.52% and -1.68%, respectively. 
The proportion of detemir-treated subjects who achieved 
an HbA1c # 7% was 36.2%, compared with 36.7% of 
glargine-treated subjects. 82.7% of the detemir-treated 
subjects and 83.8% of the glargine-treated subjects failed 
to achieve pre-supper glucose levels of #6.0 mmol/L. 
Both insulin analogs were well tolerated, with no sig-
nificant difference in the frequency of hypoglycemia. 
However, mean weight gain was significantly lower with 
detemir than with glargine (2.8 vs 3.8 kg, 95% CI -2.08 
to -0.01; P , 0.05). Overall, the detemir-treated subjects 
used more insulin than the glargine-treated subjects 
(0.82 units/kg vs 0.69 units/kg, respectively), but this 
difference disappearred when comparing only single-dose 
detemir-treated subjects who used an average daily basal 
insulin dose of 0.69 units/kg.
2.  A second trial also had a 52-week duration.40 This study 
was multinational, randomized, open-label, parallel-group 
and non-inferiority. The aim was to examine clinical out-
comes following supplementation of OADs with basal 
insulin analogs detemir or glargine in 582 insulin-naive 
type 2 DM patients. Insulin doses were in the evening 
titrated to target fasting plasma glucose #6.0 mmol/L. 
An additional morning insulin detemir dose was permit-
ted if pre-dinner FPG was .7.0 mmol/L after achieving 
FPG ,7.0 mmol/L. HbA1c and FPG decreased compar-
rably with detemir and glargine. 45% of participants 
treated with insulin detemir completed the study on 
once daily dosing and 55% of them completed on twice 
daily dosing, with no difference in HbA1c. Overall, 52% 
of patients achieved HbA1c # 7.0%: 33% (detemir) and 
35% (glargine) without hypoglycemia. Within-patient Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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variability for self-monitored FPG and pre-dinner plasma 
glucose did not differ by insulin treatment, nor did the 
relative risk of overall or nocturnal hypoglycemia. Mod-
est differences in less weight gain were seen with detemir 
vs glargine in completers (3.0 vs 3.9 kg, P = 0.01). Mean 
daily detemir dose was higher (0.78 IU/kg [0.52 with 
once-daily dosing, 1.00 IU/kg with twice-daily dosing]) 
than glargine (0.44 IU/kg). Injection site reactions were 
more frequent with detemir (4.5 vs 1.4%).
3.  Another trial comparing the two basal insulin analogs had 
a treat-to-target design.41 This 26-week study   compared 
the efficacy and safety of insulin detemir and insulin 
glargine in a basal-bolus (insulin aspart) regimen in 385 
type 2 DM patients who were randomized 2:1. Insulin 
detemir and glargine were both equally effective and 
safe treatments for glycemic control. HbA1c decreased 
significantly from the baseline in detemir to 7.1% (–1.1%, 
P , 0.001) and in glargine to 6,9% (–1.3%, P , 0.001). 
There was significantly less weight gain in the detemir 
group at comparable basal insulin dosage (1.2 ± 3.96 vs 
2.7 ± 3.94 kg, P = 0.001; 95% CI –2.19 to –0.56). At 
the end of this study, 87.4% of detemir-treated patients 
remained on a once-daily basal insulin regimen.
4. The aim of another trial was to determine whether 
glargine was non-inferior to detemir for the percentage 
of patients reaching HbA1c , 7% without symptomatic 
hypo  glycemia # 3.1 mmol/L.42 This 24-week trial exam-
ined 973 insulin-naive type 2 diabetes patients on stable 
Table 2 Randomized trials comparing insulin detemir and insulin glargine in type 2 diabetes mellitus (DM)
Study Therapy and objectives Summary of results
Hollander et al39 
N = 319 
52-week randomized (2:1), multicenter, 
open-label, parallel-group, noninferiority, 
treat-to-target
Comparison of Det and Glar added to type  
2DM who had been receiving an OAD or  
insulin, with or without OADs. 
Det, QD (evening) or BiD (morning + evening) 
or Glar, QD (evening), plus premeal insulin aspart  
existing OADs were continued but insulin 
secretagogs and a-glucosidase inhibitors were 
discontinued
Det vs Glar, P 
HbA1c -1.52% vs -1.68%, ns 
Body weight (kg) +2.8 +3.8.0.05 
within-subject variability, ns. Overall 
hypoglycemia, ns. Overall, the Det-treated 
subjects used more insulin than the Glar-
treated subjects (0.82 iUs/kg vs 0.59 iU/kg, 
respectively), but this difference disappeared 
when comparing only single-dose Det-treated 
subjects who used an average daily basal insulin 
dose of 0.69 U/kg
Rosenstock et al40 
n = 582 
52-week randomized, multicenter, open-
label, treat-to-target
Comparison of Det and Glar added to OAD in 
insulin-naive patients 
Det, QD (evening) or BiD (morning + evening) 
or Glar, QD (evening). initiate therapy at 12 
units, titrate to FPG target of ,6 mmol/L
Det vs Glar, P 
HbA1c -1.4% vs -1.5%, ns 
Body weight (kg) +3.0 vs +3.9, 0.01 
within-subject variability, ns 
Overall hypoglycemia, ns 
45% of participants completed on once-daily 
Det with mean daily dose of 0.52 iU/kg and 55% 
of them on twice-daily with mean daily dose of 
1.0 iU/kg. Mean daily dose of Glar was 0.44 iU/kg
Raskin et al41 
N = 385 
26-week randomized (2:1), multicenter, 
open-label, parallel-group, noninferiority,  
treat-to-target
Comparison of the efficacy and safety of Det 
and Glar in a basal-bolus (premeal insulin aspart) 
regimen in type 2DM
Det vs Glar, P 
HbA1c -1.1% vs-1.3%, ns 
Body weight (kg) + 1.2 vs +2.7, 0.01 
within-subject variability, ns 
Overall hypoglycemia ns 87.4% of Det-treated 
patients remained on a once-daily basal insulin 
regimen at comparable basal insulin dosage. 
Mean basal insulin doses were comparable 
between treatments (Det 0.81 vs Glar 0.75 iU/kg, 
P = 0.1)
Swinnen et al42 
N = 973 
24-week randomized, multicenter, open-
label,  
parallel-group, noninferiority, treat-to-target
Comparison of percentage of patients reaching 
HbA1c , 7% without symptomatic hypoglycemia 
#3.1 mmol/L in insulin-naive type 2 DM on  
stable OGLDs who were randomized to Glar 
once-daily or Det twice-daily
Det vs Glar, P 
HbA1c -1.54% vs -1.46%, ns 
Body weight (kg) 0.6 vs 1.4, 0.001 
Overall hypoglycemia ns 27.5% and 25.6% 
of patients reached HbA1c , 7% without 
symptomatic hypoglycemia #3.1 mmol/L. 
More patients with Det reached HbA1c , 6.5% 
(P = 0.017). Glar doses were lower than Det 
doses: 43.5 vs 76.5 iU/d (P , 0.001)
Abbreviations: Det, detemir; Glar P, glargine; Det once, detemir once-daily; Det twice, detemir twice-daily; FPG, fasting plasma glucose; ns, not significant; OAD, oral 
anti-diabetic therapy; OGLD, oral glucose-lowering drugs; QD, once daily; BiD, twice daily.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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OADs and HbA1c 7.0% to 10.5%, who were randomized 
to glargine once daily or detemir twice daily. Insulin 
doses were systematically titrated. A similar proportion 
of type 2 DM patients reached the primary outcome with 
glargine and detemir, demonstrating the non-inferiority of 
glargine. However, more detemir-treated patients reached 
HbA1c , 6.5% (P = 0.017), while hypoglycemia risk was 
similar. Weight gain was higher for glargine (1.44 ± 3.2 
and 0.6 ± 2.9 kg; difference: 0.77 kg, P , 0.001) and 
glargine doses were lower than detemir doses: 43.5 ± 29.0 
versus 76.5 ± 50.5 units/day (P , 0.001).
Effects of complex insulin regimens were examined in 
a 3-year open-label, multicenter trial that examined 708 
patients taking metformin and sulfonylurea. These subjects 
were randomly assigned to receive biphasic insulin aspart 
twice daily, prandial insulin aspart 3 times daily, or basal 
insulin detemir once daily (twice if required).43 Sulfonylurea 
therapy was replaced by a second type of insulin if hypergly-
cemia became unacceptable during the first year of the study 
or subsequently if HbA1c levels were more than 6.5%. HbA1c 
were similar for all regimens. A level of 6.5% or less was 
achieved in 31.9% of patients in the biphasic group, in 44.7% 
of patients in the prandial group (P = 0.006) and in 43.2% 
of patients in the basal group (P = 0.03). A second type of 
insulin was taken by 67.7%, 73.6%, and 81.6% of patients, 
respectively (P = 0.002). Fewer hypoglycemic episodes and 
less weight gain occurred in patients adding basal insulin.
Predictable Results and Experience in Diabetes through 
Intensification and Control to Target: an International Vari-
ability Evaluation (PREDICTIVE) was a multi-national, 
open-label, prospective, observational study assessing the 
safety and efficacy of insulin detemir in clinical practice. 
A post-hoc analysis in type 2 DM insulin-naïve patients has 
shown a benefit from adding a once-daily insulin detemir.44,45 
Improvement of glycemic control was achieved, with good 
tolerability, including a low risk of hypoglycemia and a 
weight-sparing effect.
Detemir and body weight
Insulin-related weight gain can be detrimental to the patient 
with diabetes for a number of reasons.46 The prospect of 
weight gain, coupled with concerns about hypoglycemia, 
can lead to reluctance or delay by healthcare professionals 
and patients in initiating or intensifying insulin therapy. 
Weight gain with insulin therapy has been shown to 
have potentially undesirable physiological effects, which 
include increased blood pressure, cholesterol and triglyc-
eride levels, decreased high-density lipoprotein cholesterol 
and increased waist-to-hip ratio.47 As these changes are 
known to be associated with increased cardiovascular risk, 
it is possible that they will to some extent limit the prog-
nostic benefits gained from improved glycemic control. 
Weight gain is also associated with deterioration in glyce-
mic   control, leading to an increase in insulin resistance.48 
There is therefore a need to minimize weight gain with 
insulin therapy.
Until recently, many patients had little alternative 
other than to accept unwanted weight gain if they were 
to achieve sufficient glycemic control to reduce risk of 
chronic   complications of diabetes. Insulin detemir has 
consistently been shown in randomized, controlled trials 
to have a   weight-sparing effect in both type 1 DM,49–55 and 
type 2 DM.36,56,57 This effect appears to be most prominent 
in people who are the most obese. The weight-sparing 
effects of insulin detemir have been consistently seen in 
randomized trials comparing the two basal insulin analogs 
in type 2 DM. Although insulin glargine has been shown 
to have an advantage of lower weight increase compared 
with NPH insulin in some studies, in most of these tri-
als no difference between glargine and NPH insulin was 
demonstrated.58
The mechanisms behind the weight-sparing effect of 
insulin detemir are still being clarified. Reduced risk of 
hypoglycemia with insulin detemir, coupled with a more 
consistent and reliable delivery of desired dose than is 
available with traditional basal insulin, has been proposed 
to minimize defensive snacking by patients, and help to limit 
weight gain. However, reduced risk of hypoglycemia, which 
decreases defensive snacking by patients, is unlikely to fully 
explain the weight-sparing effect of insulin detemir.59 It has 
been suggested that due to prolonged action via acylation and 
albumin binding, insulin detemir may differentially influence 
hepatocytes more than peripheral tissues, thus effectively 
suppressing hepatic glucose output without promoting 
  lipogenesis in the periphery.60
The second theory suggests that insulin detemir may be 
more effective than human insulin in communicating satiety 
signals within the central nervous system. This hypothesis 
of a direct effect of insulin detemir on the brain to reduce 
food intake was tested in healthy volunteers using the method 
of magnetoencephalography to examine the activity of the 
cerebral cortex in lean and overweight non-diabetes humans 
during a 2-step hyperinsulinemic euglycemic clamp with 
human insulin, saline infusion and insulin detemir. Despite 
cerebrocortical resistance to human insulin, insulin detemir 
increased beta activity in overweight human subjects, similar Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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to human insulin in lean subjects. The authors suggest that 
the decreased cerebral beta-activity response in overweight 
subjects can be restored by insulin detemir.61
Hallschmid et al62 compared acute effects of human 
insulin and detemir on EEG measures and food intake in 15 
healthy men during 2 hyperinsulinemic euglycemic clamps 
that included an insulin bolus injection (human insulin, 
detemir) followed by a steady 90-minute infusion. Twenty 
minutes after infusion, subjects were allowed to eat ad libitum 
from a test buffet. While inducing   comparable peripheral 
effects, detemir exerted stronger acute effects on brain func-
tions than human insulin (it induced a negative DC-potential 
shift that was not observed during human insulin infusion) 
and triggered a relative decrease in food consumption – by 
303 kcal (P , 0.04), suggesting an enhanced anorexigenic 
impact of detemir compared to human insulin on central 
nervous networks that control nutrient uptake.
Safety and tolerability
Beside influencing glucose metabolism, insulin exerts other 
biological functions such as proliferation, differentiation, 
and cell apoptosis. Insulin activity is driven through specific 
insulin receptors. At low concentrations its intercellular activ-
ity leads to a very quick appearance of metabolic effects. At 
higher concentrations insulin affects processes such as growth 
promotion by binding and stimulating insulin-like growth 
factor type I(IGF-I).63 The B26-B30 region of the insulin 
molecule has been critical for insulin receptor recognition, 
but the C-terminal end of the insulin B chain seems to be 
important in insulin binding to the IGF-I receptor. Multiple 
factors such as residence time on the receptor, dissociation 
rate, rate of receptor internalization and the degree of phos-
phorylation of signaling proteins can affect the mitogenic 
potencies of insulin analogs.64
Insulin analogs were developed to modify the structure 
of the human insulin molecule in order to more accurately 
approximate the endogenous secretion of insulin. Changing 
the structure of the insulin molecule, however, may signifi-
cantly alter both its metabolic and mitogenic activity and have 
raised concerns about the safety of the insulin analogs.63
There is epidemiological evidence that diabetes is an 
independent predictor of cancer of the breast, colon, blad-
der, liver, pancreas and endometrium. However, clinical 
data on the relationship between risk of cancer and insulin 
treatment are sparse. IGF-I has been implicated as playing 
an important role in the progression and, potentially, in the 
development of human cancers. Epidemiological data have 
revealed that patients with high levels of IGF-I have an 
increased risk of developing cancer compared with those 
with IGF-I levels in the low and normal ranges. Last but not 
least, based on the expected role of IGF-I in tumor growth, 
anti-IGF-I receptor antibodies have been explored for the 
treatment of certain cancers.65
A mitogenic potential of insulin analogs (lispro, aspart, 
detemir and glargine) was studied by Kurtzhals et al66 using an 
experiment with human osteosarcoma cells. The   rapid-acting 
insulin analogs aspart and lispro resembled human insulin in 
all parameters. In this experiment with human osteosarcoma 
cells, the long-acting basal analog detemir had decreased 
IGF-I receptor affinity and   mitogenicity, but insulin glargine 
had increases in both of them.   However, based on studies 
performed in vitro with different cell lines, the increased 
mitogenic potency was observed only in the studies with 
human osteosarcoma cells.63 A very recent metaanalysis of 
randomized, controlled basal insulin analog trials65 did not 
show any increased risk for having a cancer in patients treated 
with detemir, glargine and NPH insulin.
Wada et al67 studied intracellular signaling properties 
of NPH, glargine and detemir insulins in various cultured 
cells and receptors. For the metabolic signaling, glargine 
and NPH insulin induced comparable dose-dependent 
phosphorylation of the studied receptors, whereas detemir-
induced kinetics were markedly lower in adipocytes and 
myocytes. The authors concluded that their results indicate 
that glargine has comparable properties to human insulin in 
metabolic and mitogenic signaling and action. In contrast, 
detemir-induced metabolic signaling was less potent in all 
cell types studied, and it was reduced further by increasing 
concentrations of albumin.
Based on published clinical data from different studies 
which did not have sufficiently long-term duration and size, 
it is not possible to draw definite conclusions on the risk of 
cancer promotion by insulin analogs.
Conclusions
Insulin detemir is a basal insulin analog that provides an effective 
therapeutic option for patients with type 1 and type 2 DM, which 
is in agreement with recent guidelines.25 For glycemic control, 
no significant differences were found in HbA1c levels when 
insulin detemir is compared with NPH insulin.
However, it has been demonstrated that insulin detemir is 
responsible for significantly lower within-subject variability 
than NPH insulin and insulin glargine. Detemir is comparable 
with insulin glargine in significantly reducing the rate of all 
types of hypoglycemia. But this insulin provides the more 
favorable clinical benefit of no or less weight gain than NPH Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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insulin and glargine. Recent pharmacodynamic studies have 
shown that detemir can be used once daily in many patients 
with diabetes. Patients can be safely switched from one basal 
insulin to another, but close monitoring during transition is 
necessary as there may be dose differences with require-
ments for a higher dose of insulin detemir.68 Together with 
  patient-friendly injection devices and dose adjustments, it 
provides a treatment option with the potential to lower the 
key barriers of adherence to insulin therapy in type 2 DM. 
Moreover, confusing results of an intensive treatment of 
hyperglycemia on cardiovascular outcomes in type 2 DM, 
which were recently discussed intensively,32 have indepen-
dently suggested starting intensive therapy of hyperglycemia 
at an early stage of diabetes and to prefer those therapeutic 
options which provide the possibility to reach HbA1c goals 
individually with a low risk of hypoglycemia or other adverse 
effects of treatment. The properties of insulin detemir 
  correspond with these requirements.
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